Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate CancerPhilip W. Kantoff, Wayne R. Godfrey, Reiner Laus et al.|Journal of Clinical Oncology|2010Cited by 973
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate CancerJames L. Gulley, William L. Dahut, Jennifer L. Marté et al.|Clinical Cancer Research|2005Cited by 371
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A. Madan, James L. Gulley, Mahsa Mohebtash et al.|The Lancet Oncology|2012Cited by 327
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, William L. Dahut, David James VanderWeele et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 312
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerJames L. Gulley, Jeffrey Schlom, Philip M. Arlen et al.|Cancer Immunology Immunotherapy|2009Cited by 298